JPH10245391A5 - - Google Patents
Info
- Publication number
- JPH10245391A5 JPH10245391A5 JP1997047963A JP4796397A JPH10245391A5 JP H10245391 A5 JPH10245391 A5 JP H10245391A5 JP 1997047963 A JP1997047963 A JP 1997047963A JP 4796397 A JP4796397 A JP 4796397A JP H10245391 A5 JPH10245391 A5 JP H10245391A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- acceptable salt
- active ingredient
- physiologically acceptable
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9047963A JPH10245391A (ja) | 1997-03-03 | 1997-03-03 | ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9047963A JPH10245391A (ja) | 1997-03-03 | 1997-03-03 | ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10245391A JPH10245391A (ja) | 1998-09-14 |
| JPH10245391A5 true JPH10245391A5 (OSRAM) | 2004-12-02 |
Family
ID=12790005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9047963A Pending JPH10245391A (ja) | 1997-03-03 | 1997-03-03 | ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10245391A (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| EP1273578B1 (en) | 2001-06-28 | 2005-02-23 | Dainippon Ink And Chemicals, Inc. | Benzopyran derivatives and antiallergic agent containing the same |
| TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
| CA2725047A1 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| US9545610B2 (en) | 2013-03-04 | 2017-01-17 | Nova Chemicals (International) S.A. | Complex comprising oxidative dehydrogenation unit |
| CN104945455B (zh) * | 2014-03-28 | 2019-01-01 | 中国医学科学院药物研究所 | 香豆素苷类化合物、其制法和药物组合物与用途 |
| CN104861020B (zh) * | 2015-06-14 | 2017-05-17 | 海南医学院 | 一个苯丙素苷类化合物、其提取方法及其应用 |
| PE20210644A1 (es) | 2018-07-19 | 2021-03-23 | Astrazeneca Ab | METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA |
| WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| US20240212818A1 (en) | 2021-04-01 | 2024-06-27 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition |
| TW202525278A (zh) | 2023-12-15 | 2025-07-01 | 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 | 治療慢性腎病及高血壓之方法 |
-
1997
- 1997-03-03 JP JP9047963A patent/JPH10245391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10245391A5 (OSRAM) | ||
| CA2136999A1 (en) | Peripheral vasodilating agent containing piperidine derivative as active ingredient | |
| CA2382480A1 (en) | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | |
| CA2015475A1 (en) | Treating agent for osteoarthritis | |
| NO963053D0 (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
| CA2341568A1 (en) | Stabilized pharmaceutical composition in lyophilized form | |
| IL112515A (en) | Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus | |
| CA2102591A1 (en) | Hypoglycemic Agent | |
| CA2257016A1 (en) | Imidazolidin-4-one derivatives useful as anticancer agents | |
| KR930703303A (ko) | 1, 4-벤조티아제핀 유도체 | |
| JP2002519425A5 (OSRAM) | ||
| CA2190993A1 (en) | Protective agent for organ or tissue | |
| RU2003134629A (ru) | Соединения цефема | |
| CA2365359A1 (en) | Medicaments containing a sulfopyranosylglycerol derivative | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| JP2000169325A5 (OSRAM) | ||
| CA2317673A1 (en) | Novel allylthiopyridazine derivatives and process for preparing the same | |
| CA2373484A1 (en) | Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs | |
| EP1103253A3 (en) | Aqueous film coating agent and oral solid preparation | |
| IT1254280B (it) | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson | |
| KR950032264A (ko) | 7-글리코실옥시벤조피란 유도체 및 이를 활성 성분으로서 함유하는 항알레르기제 | |
| RU97112927A (ru) | Новое аминоолигосахаридное производное и способ его получения | |
| CA2195031A1 (en) | Quinolinone derivative and anti-allergic agent with said quinolinone derivative as the active ingredient | |
| CA2438506A1 (en) | Use of a cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications | |
| EP0997473A4 (en) | NATURAL ANTITUMOR OR ANTIVIRAL SUBSTANCES AND THEIR USE |